Concert Pharmaceuticals
(NASDAQ) CNCE
Concert Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$56.58K
Net Income (TTM)
$66.45M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
CNCE News
3 Biotech Stocks to Buy in March
CNCE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Concert Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
64
CEO
Roger D. Tung, PhD
Website
www.concertpharma.comHeadquarters
Lexington, MA 02421, US
CNCE Financials
Key Financial Metrics (TTM)
Gross Margin
100%
Operating Margin
-2%
Net Income Margin
-3%
Return on Equity
-68%
Return on Capital
-52%
Return on Assets
-50%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$32.58M
Operating Income
$77.51M
EBITDA
$73.49M
Operating Cash Flow
$55.15M
Capital Expenditure
$255.00K
Free Cash Flow
$55.41M
Cash & ST Invst.
$143.10M
Total Debt
$15.06M
Concert Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$8.00K
-98.5%
Gross Profit
$8.00K
-98.5%
Gross Margin
100.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
64
N/A
Net Income
$28.20M
-5.7%
EBITDA
$30.00M
-14.0%
Quarterly Fundamentals
Net Cash
$135.32M
+48.8%
Accounts Receivable
$1.65M
+246.2%
Inventory
$0.00
N/A
Long Term Debt
$12.87M
-9.5%
Short Term Debt
$1.34M
+22.7%
Return on Assets
-49.96%
N/A
Return on Invested Capital
-51.95%
N/A
Free Cash Flow
$26.05M
-39.1%
Operating Cash Flow
$25.96M
-39.3%